Gade-Rasmussen Birthe, Madsbad Sten, Svane Maria Saur, Martinussen Christoffer, Hansen Torben
Ugeskr Laeger. 2018 Nov 12;180(46).
In this case report a 40-year-old insulin-treated male patient presented with a KCNJ11 R201H mutation, which can cause neonatal diabetes. After initiation of treatment with high doses of the sulfonylurea glibencamide in combination with the glucagon-like peptide 1 receptor agonist liraglutide, insulin treatment of the patient could be terminated. The first nine months after termination of insulin treatment the glycated haemoglobin concentration was 48-54 mmol/mol (i.e. 6.5-7.1%).
在本病例报告中,一名40岁接受胰岛素治疗的男性患者存在可导致新生儿糖尿病的KCNJ11 R201H突变。在用高剂量磺脲类药物格列本脲联合胰高血糖素样肽1受体激动剂利拉鲁肽开始治疗后,该患者的胰岛素治疗得以终止。胰岛素治疗终止后的前九个月,糖化血红蛋白浓度为48 - 54 mmol/mol(即6.5 - 7.1%)。